RAFAEL
RUBIO GARCÍA
Profesor titular de universidad
![Foto de RAFAEL](/img/uploaded/6CA654DD031F6FEF08160B3A8AA5CC20.jpg)
![Foto de Hospital Universitari Germans Trias i Pujol](/img/noimage_org.png)
Hospital Universitari Germans Trias i Pujol
Barcelona, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitari Germans Trias i Pujol (59)
2024
-
Acceptability of Long-Acting Injectable Antiretroviral Treatment for HIV Management: Perspectives of Patients and Physicians in Spain
AIDS Patient Care and STDs, Vol. 38, Núm. 7, pp. 305-314
2022
-
Discovering HIV related information by means of association rules and machine learning
Scientific Reports, Vol. 12, Núm. 1
-
Low CD4/CD8 ratio is associated with increased morbidity and mortality in late and non-late presenters: results from a multicentre cohort study, 2004-2018
BMC infectious diseases, Vol. 22, Núm. 1, pp. 379
-
Predictors of low-level HIV viraemia and virological failure in the era of integrase inhibitors: A Spanish nationwide cohort
HIV Medicine, Vol. 23, Núm. 8, pp. 825-836
2021
-
Determinants of hiv-1 late presentation in patients followed in europe
Pathogens, Vol. 10, Núm. 7
-
Redefining therapeutic success in HIV patients: An expert view
Journal of Antimicrobial Chemotherapy, Vol. 76, Núm. 10, pp. 2501-2518
2020
-
Virological outcome among HIV infected patients transferred from pediatric care to adult units in Madrid, Spain (1997–2017)
Scientific Reports, Vol. 10, Núm. 1
2019
-
Executive summary of the GeSIDA/National AIDS Plan consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2018)
Enfermedades Infecciosas y Microbiologia Clinica, Vol. 37, Núm. 3, pp. 195-202
2018
-
GESIDA/PETHEMA recommendations on the diagnosis and treatment of lymphomas in patients infected by the human immunodeficiency virus
Medicina Clinica, Vol. 151, Núm. 1, pp. 39.e1-39.e17
-
Impact of co-infection by hepatitis C virus on immunological and virological response to antiretroviral therapy in HIV-positive patients
Medicine (United States), Vol. 97, Núm. 38
-
Low-level viremia is associated with clinical progression in HIV-infected patients receiving antiretroviral treatment
Journal of Acquired Immune Deficiency Syndromes, Vol. 78, Núm. 3, pp. 329-337
2017
-
Eradication of hepatitis C virus and non-liver-related non–acquired immune deficiency syndrome–related events in human immunodeficiency virus/hepatitis C virus coinfection
Hepatology, Vol. 66, Núm. 2, pp. 344-356
-
Prediction of long-term outcomes of HIV-infected patients developing non-AIDS events using a multistate approach
PLoS ONE, Vol. 12, Núm. 9
-
Simplification to dual therapy (atazanavir/ritonavir1lamivudine) versus standard triple therapy [atazanavir/ritonavir1two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study)
Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 1, pp. 246-253
2016
-
Impact of late presentation of HIV infection on short-, mid- and long-term mortality and causes of death in a multicenter national cohort: 2004-2013
Journal of Infection, Vol. 72, Núm. 5, pp. 587-596
-
MicroRNA profile in CD8+ T-lymphocytes from HIV-infected individuals: Relationship with antiviral immune response and disease progression
PLoS ONE, Vol. 11, Núm. 5
-
The F4/AS01B HIV-1 Vaccine Candidate Is Safe and Immunogenic, but Does Not Show Viral Efficacy in Antiretroviral Therapy-Naive, HIV-1-Infected Adults: A Randomized Controlled Trial
Medicine (United States), Vol. 95, Núm. 6
2015
-
Comparison of the prognostic value of liver biopsy and FIB-4 index in patients coinfected with HIV and hepatitis C virus
Clinical Infectious Diseases, Vol. 60, Núm. 6, pp. 950-958
-
Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study
PLoS Medicine, Vol. 12, Núm. 3
-
Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial
The Lancet Infectious Diseases, Vol. 15, Núm. 7, pp. 775-784